Cargando…

Individualizing anaemia therapy

Individualized strategies for managing renal anaemia with erythropoiesis-stimulating agents (ESAs) need to be advanced. Recent outcomes from clinical studies prompted a narrowing of the guideline-recommended haemoglobin target (11–12 g/dL) due to increased mortality and morbidity when targeting high...

Descripción completa

Detalles Bibliográficos
Autor principal: de Francisco, Angel L.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421434/
https://www.ncbi.nlm.nih.gov/pubmed/25949459
http://dx.doi.org/10.1093/ndtplus/sfq164
_version_ 1782369868390072320
author de Francisco, Angel L.M.
author_facet de Francisco, Angel L.M.
author_sort de Francisco, Angel L.M.
collection PubMed
description Individualized strategies for managing renal anaemia with erythropoiesis-stimulating agents (ESAs) need to be advanced. Recent outcomes from clinical studies prompted a narrowing of the guideline-recommended haemoglobin target (11–12 g/dL) due to increased mortality and morbidity when targeting higher haemoglobin concentrations. Maintaining a narrow target is a clinical challenge, as haemoglobin concentration tends to fluctuate. The goal of individualized treatment is to achieve the haemoglobin target at the lowest ESA dose while avoiding significant fluctuations in haemoglobin concentrations and persistently low or high concentrations. This may require changes to the ESA dose and dosing frequency over the course of treatment.
format Online
Article
Text
id pubmed-4421434
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44214342015-05-06 Individualizing anaemia therapy de Francisco, Angel L.M. NDT Plus In-Depth Clinical Review Individualized strategies for managing renal anaemia with erythropoiesis-stimulating agents (ESAs) need to be advanced. Recent outcomes from clinical studies prompted a narrowing of the guideline-recommended haemoglobin target (11–12 g/dL) due to increased mortality and morbidity when targeting higher haemoglobin concentrations. Maintaining a narrow target is a clinical challenge, as haemoglobin concentration tends to fluctuate. The goal of individualized treatment is to achieve the haemoglobin target at the lowest ESA dose while avoiding significant fluctuations in haemoglobin concentrations and persistently low or high concentrations. This may require changes to the ESA dose and dosing frequency over the course of treatment. Oxford University Press 2010-12 2010-09-21 /pmc/articles/PMC4421434/ /pubmed/25949459 http://dx.doi.org/10.1093/ndtplus/sfq164 Text en © The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle In-Depth Clinical Review
de Francisco, Angel L.M.
Individualizing anaemia therapy
title Individualizing anaemia therapy
title_full Individualizing anaemia therapy
title_fullStr Individualizing anaemia therapy
title_full_unstemmed Individualizing anaemia therapy
title_short Individualizing anaemia therapy
title_sort individualizing anaemia therapy
topic In-Depth Clinical Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421434/
https://www.ncbi.nlm.nih.gov/pubmed/25949459
http://dx.doi.org/10.1093/ndtplus/sfq164
work_keys_str_mv AT defranciscoangellm individualizinganaemiatherapy